Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Binglian Qingyan is a Traditional Chinese Medicine (TCM) spray formulation developed by Wuhan Union Hospital (affiliated with Tongji Medical College of Huazhong University of Science and Technology). It is primarily indicated for the treatment of acute pharyngitis and acute exacerbations of chronic pharyngitis. The preparation is designed to provide local relief of throat pain and inflammation through its heat-clearing and detoxifying properties. In clinical studies, its efficacy and safety have been evaluated in comparison to other common throat treatments such as Jinsangzi tablets and Jinhoujian spray. As a hospital-made preparation, it represents a localized therapeutic option within the Chinese medical system for upper respiratory inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Binglian Qingyan.